Premium
N‐acetylcysteine (NAC) Improves but does not Prevent the Appearance of Heart Failure in Syrian Cardiomyopathic Hamsters.
Author(s) -
Cruz Nildris,
Quidgley Jose,
Escobales Nelson,
Altieri Pablo,
Crespo Maria J.
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.lb57
Subject(s) - acetylcysteine , heart failure , medicine , ejection fraction , oxidative stress , antioxidant , cardiology , cardiac function curve , dilated cardiomyopathy , cardiomyopathy , endocrinology , chemistry , biochemistry
Oxidative stress has been postulated to contribute to the etiology of heart failure (HF). The efficacy of antioxidant therapy in HF, however, remains controversial. This study evaluates the effect of the antioxidant N‐acetylcysteine (NAC, 1g/kg/day) on cardiovascular function in 2‐ and 6‐month‐old Bio‐TO2 Syrian cardiomyopathic hamsters (SCH) after 1‐month and 5‐month treatment with this drug. Endothelial function, systolic blood pressure (SBP), and echocardiographic parameters were evaluated. One month of NAC administration normalized the increased SBP observed in 2‐month‐old SCH (n=5, P<0.05). Five‐month treatment with NAC, improved 24% (P<0.05) the EMax value from the Ach‐induced relaxation (from 45.8± 4 % to 56.1 ± 2 % n= 7) while did not modify EC50 or SBP. Ejection fraction increased 39±4 % (n=11, P<0.05) and cardiac output index improved but did not reach statistical significance. In addition, LVEDV and LVESV were significantly reduced by NAC (P<0.05), These results suggest that antioxidant therapy alone improves cardiovascular function in this animal model of dilated cardiomyopathy. The treatment, however, does not prevent the appearance of HF. Supported by NIH‐SCORE S06‐RR 08224.